Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced Breast Cancer
Interventions: DRUG: LDE225|DRUG: Docetaxel
Sponsor: Spanish Breast Cancer Research Group
Collaborators: Novartis